Abstract
Adult-onset Still’s disease (AOSD) is a rare, systemic inflammatory disease of unknown aetiology, characterized by daily high spiking fevers, evanescent rash and arthritis. Our objective was to review the most recent medical literature regarding advances in the understanding of disease pathogenesis, diagnosis and treatment. There is no single diagnostic test for AOSD, and diagnosis is based on clinical criteria and usually necessitates the exclusion of infectious, neoplastic and autoimmune diseases. Laboratory tests are nonspecific and reflect heightened immunological activity with leukocytosis, elevated acute phase reactants and, in particular, extremely elevated serum ferritin levels. Abnormal serum liver function tests are common, while rheumatoid factor and antinuclear antibodies are usually absent. Recent studies of the pathogenesis of the disease have suggested an important role for cytokines. Interleukin (IL)-1, IL-6 and IL-18, macrophage colony-stimulating factor, interferon-γ and tumour necrosis factor (TNF)-α are all elevated in patients with AOSD. Prognosis depends on the course of the disease and tends to be more favourable when systemic symptoms predominate.
Treatment includes the use of corticosteroids, often in combination with immunosuppressants (e.g. methotrexate, gold, azathioprine, leflunomide, tacrolimus, ciclosporin and cyclophosphamide) and intravenous immunoglobulin. Biological agents (e.g. anti-TNFα, anti-IL-1 and anti-IL-6) have been successfully used in refractory cases. Further progress has been hampered by the rarity and heterogeneity of the disease, which has not permitted the execution of randomized controlled studies.
Similar content being viewed by others
References
Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still’s disease. Ann Rheum Dis 2006 May; 65(5): 564–72
Bywaters EG. Still’s disease in the adult. Ann Rheum Dis 1971 Mar; 30(2): 121–33
Magadur-Joly G, Billaud E, Barrier JH, et al. Epidemiology of adult Still’s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 1995 Jul; 54(7): 587–90
Ohta A, Yamaguchi M, Kaneoka H, et al. Adult Still’s disease: review of 228 cases from the literature. J Rheumatol 1987 Dec; 14(6): 1139–46
Wakai K, Ohta A, Tamakoshi A. Estimated prevalence and incidence of adult Still’s disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol 1997; 7: 221–5
Ohta A, Yamaguchi M, Tsunematsu T, et al. Adult Still’s disease: a multicenter survey of Japanese patients. J Rheumatol 1990 Aug; 17(8): 1058–63
Sampalis JS, Medsger Jr TA, Fries JF, et al. Risk factors for adult Still’s disease. J Rheumatol 1996 Dec; 23(12): 2049–54
Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 1991 Mar; 70(2): 118–36
Wouters JM, Reekers P, van de Putte LB. Adult-onset Still’s disease. Disease course and HLA associations. Arthritis Rheum 1986 Mar; 29(3): 415–8
Miller ML, Aaron S, Jackson J, et al. HLA gene frequencies in children and adults with systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 1985 Feb; 28(2): 146–50
Joung CI, Lee HS, Lee SW, et al. Association between HLA-DR B1 and clinical features of adult onset Still’s disease in Korea. Clin Exp Rheumatol 2003 Jul–Aug; 21(4): 489–92
Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still’s disease. Association with chronic articular disease. Rheumatology (Oxford) 2001 Dec; 40(12): 1398–404
Chen DY, Lan JL, Hsieh TY, et al. Clinical manifestations, disease course, and complications of adult-onset Still’s disease in Taiwan. J Formos Med Assoc 2004 Nov; 103(11): 844–52
Masson C, Le Loet X, Liote F, et al. Adult Still’s disease: part I. Manifestations and complications in sixty-five cases in France. Rev Rhum Engl Ed 1995 Dec; 62(11): 748–57
Andres E, Kurtz JE, Perrin AE, et al. Retrospective monocentric study of 17 patients with adult Still’s disease, with special focus on liver abnormalities. Hepatogastroenterology 2003 Jan–Feb; 50(49): 192–5
van de Putte LB, Wouters JM. Adult-onset Still’s disease. Bailliere’s Clin Rheumatol 1991 Aug; 5(2): 263–75
Pay S, Turkcapar N, Kalyoncu M, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol 2006 Sep; 25(5): 639–44
Mert A, Ozaras R, Tabak F, et al. Fever of unknown origin: a review of 20 patients with adult-onset Still’s disease. Clin Rheumatol 2003 May; 22(2): 89–93
Bambery P, Thomas RJ, Malhotra HS, et al. Adult onset Still’s disease: clinical experience with 18 patients over 15 years in northern India. Ann Rheum Dis 1992 Apr; 51(4): 529–32
Singh S, Samant R, Joshi VR. Adult onset Still’s disease: a study of 14 cases. Clin Rheumatol 2008 Jan; 27(1): 35–9
Akritidis N, Sakkas LI. Adult onset Still’s disease. 16 cases. Presse Med 1995 Sep 16; 24(26): 1207–8
Evensen KJ, Nossent HC. Epidemiology and outcome of adult-onset Still’s disease in northern Norway. Scand J Rheumatol 2006 Jan–Feb; 35(1): 48–51
Pouchot J, Ouakil H, Debin ML, et al. Adult Still’s disease associated with acute human parvovirus B19 infection. Lancet 1993 May 15; 341(8855): 1280–1
Longo G, Luppi M, Bertesi M, et al. Still’s disease, severe thrombocytopenia, and acute hepatitis associated with acute parvovirus B19 infection. Clin Infect Dis 1998 Apr; 26(4): 994–5
Wouters JM, van der Veen J, van de Putte LB, et al. Adult onset Still’s disease and viral infections. Ann Rheum Dis 1988 Sep; 47(9): 764–7
Kadar J, Petrovicz E. Adult-onset Still’s disease. Best Pract Res Clin Rheumatol 2004 Oct; 18(5): 663–76
Perez C, Artola V. Adult Still’s disease associated with Mycoplasma pneumoniae infection. Clin Infect Dis 2001 Mar 15; 32(6): E105–6
Saviola G, Abdi Ali L, Shams Eddin S, et al. Clarithromycin in adult-onset Still’s disease: case report with a 1-year follow-up. Clin Exp Rheumatol 2004 May–Jun; 22(3): 379
Chen DY, Lan JL, Lin FJ, et al. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still’s disease. Ann Rheum Dis 2004 Oct; 63(10): 1300–6
Chen DY, Lan JL, Lin FJ, et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. J Rheumatol 2004 Nov; 31(11): 2189–98
Hoshino T, Ohta A, Yang D, et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still’s disease. J Rheumatol 1998 Feb; 25(2): 396–8
Sugiura T, Kawaguchi Y, Harigai M, et al. Association between adult-onset Still’s disease and interleukin-18 gene polymorphisms. Genes Immun 2002 Nov; 3(7): 394–9
Ogata A, Kitano M, Yamanaka J, et al. Interleukin 18 and hepatocyte growth factor in fulminant hepatic failure of adult onset Still’s disease. J Rheumatol 2003 May; 30(5): 1093–6
Chen DY, Lan JL, Lin FJ, et al. Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still’s disease. Arthritis Rheum 2005 Jun 15; 53(3): 320–7
Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol 1992 Mar; 19(3): 424–30
Cush JJ, Medsger Jr TA, Christy WC, et al. Adult-onset Still’s disease: clinical course and outcome. Arthritis Rheum 1987 Feb; 30(2): 186–94
Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset Still disease. Medicine (Baltimore) 2002 May; 81(3): 194–200
Zhiyong Z, Bingjun L, Xiaoju L, et al. Fever of unknown origin: a report from China of 208 cases. Int J Clin Pract 2003 Sep; 57(7): 592–6
Wouters JM, van de Putte LB. Adult-onset Still’s disease; clinical and laboratory features, treatment and progress of 45 cases. Q J Med 1986 Nov; 61(235): 1055–65
Larson EB. Adult Still’s disease: recognition of a clinical syndrome and recent experience. West J Med 1985 May; 142(5): 665–71
Cush JJ. Adult-onset Still’s disease. Bull Rheum Dis 2000; 49(6): 1–4
Medsger Jr TA, Christy WC. Carpal arthritis with ankylosis in late onset Still’s disease. Arthritis Rheum 1976 Mar–Apr; 19(2): 232–42
Bjorkengren AG, Pathria MN, Sartoris DJ, et al. Carpal alterations in adult-onset Still disease, juvenile chronic arthritis, and adult-onset rheumatoid arthritis: comparative study. Radiology 1987 Nov; 165(2): 545–8
Cabane J, Michon A, Ziza JM, et al. Comparison of long term evolution of adult onset and juvenile onset Still’s disease, both followed up for more than 10 years. Ann Rheum Dis 1990 May; 49(5): 283–5
Dino O, Provenzano G, Giannuoli G, et al. Fulminant hepatic failure in adult onset Still’s disease. J Rheumatol 1996; 23: 784–5
McFarlane M, Harth M, Wall WJ. Liver transplant in adult Still’s disease. J Rheumatol 1997 Oct; 24(10): 2038–41
Hirohata S, Kamoshita H, Taketani T, et al. Adult Still’s disease complicated with adult respiratory distress. Arch Intern Med 1986 Dec; 146(12): 2409–10
Stoica GS, Cohen RI, Rossoff LJ. Adult Still’s disease and respiratory failure in a 74 year old woman. Postgrad Med J 2002 Feb; 78(916): 97–8
Suleiman M, Wolfovitz E, Boulman N, et al. Adult onset Still’s disease as a cause of ARDS and acute respiratory failure. Scand J Rheumatol 2002; 31(3): 181–3
Sachs RN, Talvard O, Lanfranchi J. Myocarditis in adult Still’s disease. Int J Cardiol 1990 Jun; 27(3): 377–80
Bennett AN, Peterson P, Sangle S, et al. Adult onset Still’s disease and collapsing glomerulopathy: successful treatment with intravenous immunoglobulins and mycophenolate mofetil. Rheumatology (Oxford) 2004 Jun; 43(6): 795–9
Kumar S, Sheaff M, Yaqoob M. Collapsing glomerulopathy in adult still’s disease. Am J Kidney Dis 2004 May; 43(5): e4–10
Wendling D, Hory B, Blanc D. Adult Still’s disease and mesangial glomerulonephritis: report of two cases. Clin Rheumatol 1990; 9: 95–9
Wendling D, Humbert PG, Billerey C, et al. Adult onset Still’s disease and related renal amyloidosis. Ann Rheum Dis 1991 Apr; 50(4): 257–9
Arlet JB, Le TH, Marinho A, et al. Reactive haemophagocytic syndrome in adult onset Still’s disease: report of 6 patients and review of the literature. Ann Rheum Dis 2006 Dec; 65(12): 1596–601
Denault A, Dimopoulos MA, Fitzcharles MA. Meningoencephalitis and peripheral neuropathy complicating adult Still’s disease. J Rheumatol 1990 May; 17(5): 698–700
Markusse HM, Stolk B, van der Mey AG, et al. Sensorineural hearing loss in adult onset Still’s disease. Ann Rheum Dis 1988 Jul; 47(7): 600–2
Fautrel B, Le Moel G, Saint-Marcoux B, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. J Rheumatol 2001 Feb; 28(2): 322–9
Fautrel B. Ferritin levels in adult Still’s disease: any sugar? Joint Bone Spine 2002 Jun; 69(4): 355–7
Van Reeth C, Le Moel G, Lasne Y, et al. Serum ferritin and isoferritins are tools for diagnosis of active adult Still’s disease. J Rheumatol 1994 May; 21(5): 890–5
Akritidis N, Giannakakis Y, Sakkas L. Very high serum ferritin levels in adult-onset Still’s disease. Br J Rheumatol 1997 May; 36(5): 608–9
Akritidis N, Giannakakis I, Giouglis T. Ferritin levels and response to treatment in patients with adult Still’s disease. J Rheumatol 1996 Jan; 23(1): 201–2
Kirino Y, Takeno M, Iwasaki M, et al. Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still’s disease: use in the differential diagnosis of hyperferritinemia. Arthritis Res Ther 2005; 7(3): R616–24
Min JK, Cho CS, Kim HY, et al. Bone marrow findings in patients with adult Still’s disease. Scand J Rheumatol 2003; 32(2): 119–21
Fujii T, Suwa A, Mimori T, et al. Chronic arthritis and carpo:metacarpal ratio in Japanese patients with adult Still’s disease. J Rheumatol 1998 Dec; 25(12): 2402–7
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971 Jun 23; 231(25): 232–5
Masson C, Le Loet X, Liote F, et al. Adult Still’s disease: part II. Management, outcome, and prognostic factors. Rev Rhum Engl Ed 1995 Dec; 62(11): 758–65
Li YH, Brauner A, Jonsson B, et al. Inhibition of macrophage proinflammatory cytokine expression by steroids and recombinant IL-10. Biol Neonate 2001 Aug; 80(2): 124–32
Hu X, Li WP, Meng C, et al. Inhibition of IFN-gamma signaling by glucocorticoids. J Immunol 2003 May 1; 170(9): 4833–9
Migita K, Eguchi K, Kawabe Y, et al. Apoptosis induction in human peripheral blood T lymphocytes by high-dose steroid therapy. Transplantation 1997 Feb 27; 63(4): 583–7
De A, Blotta HM, Mamoni RL, et al. Effects of dexamethasone on lymphocyte proliferation and cytokine production in rheumatoid arthritis. J Rheumatol 2002 Jan; 29(1): 46–51
Nakano T, Ohara O, Teraoka H, et al. Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. J Biol Chem 1990 Jul 25; 265(21): 12745–8
Khraishi M, Fam AG. Treatment of fulminant adult Still’s disease with intravenous pulse methylprednisolone therapy. J Rheumatol 1991 Jul; 18(7): 1088–90
Koizumi R, Tsukada Y, Ideura H, et al. Treatment of adult Still’s disease with dexamethasone, an alternative to prednisolone. Scand J Rheumatol 2000; 29(6): 396–8
Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006 Mar; 65(3): 285–93
Shojania K, Chalmers A, Rangno K. Cyclosporin A in the treatment of adult Still’s disease. J Rheumatol 1995 Jul; 22(7): 1391–2
Cefle A. Leflunomide and azathioprine combination in refractory adult-onset Still’s disease. Ann Pharmacother 2005 Apr; 39(4): 764–7
Elkon KB, Hughes GR, Bywaters EG, et al. Adult-onset Still’s disease: twenty-year followup and further studies of patients with active disease. Arthritis Rheum 1982 Jun; 25(6): 647–54
Murakami K, Fujii T, Yukawa N, et al. Successful treatment of a patient with refractory adult Still’s disease by tacrolimus. Modern Rheumatology / the Japan Rheumatism Association 2007; 17(2): 167–70
Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002; 4(4): 266–73
Cronstein BN, Naime D, Ostad E. The antiinflammatory effects of methotrexate are mediated by adenosine. Adv Expe Med Biol 1994; 370: 411–6
Cronstein BN, Eberle MA, Gruber HE, et al. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A 1991 Mar 15; 88(6): 2441–5
Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still’s disease. J Rheumatol 1999 Feb; 26(2): 373–8
Fujii T, Akizuki M, Kameda H, et al. Methotrexate treatment in patients with adult onset Still’s disease: retrospective study of 13 Japanese cases. Ann Rheum Dis 1997 Feb; 56(2): 144–8
Aydintug AO, D’Cruz D, Cervera R, et al. Low dose methotrexate treatment in adult Still’s disease. J Rheumatol 1992 Mar; 19(3): 431–5
Asherson RA, Pascoe L. Adult onset Still’s disease: response to Enbrel. Ann Rheum Dis 2002 Sep; 61(9): 859–60; author reply 60
Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum 2002 May; 46(5): 1171–6
Cavagna L, Caporali R, Epis O, et al. Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol 2001 May–Jun; 19(3): 329–32
Kokkinos A, Iliopoulos A, Greka P, et al. Successful treatment of refractory adult-onset Still’s disease with infliximab: a prospective, non-comparative series of four patients. Clin Rheumatol 2004 Feb; 23(1): 45–9
Huffstutter J, Sienknecht C. Treatment of resistant adult Still’s disease with infliximab: a report of 2 cases. J Clin Rheumatol 2004; 10(4): 218–21
Bonilla Hernan MG, Cobo Ibanez T, de Miguel Mendieta E, et al. Infliximab (anti-TNF-alpha) treatment in patients with adult Still’s disease: experience in 2 cases [in Spanish]. An Med Interna 2004 Jan; 21(1): 23–6
Caramaschi P, Biasi D, Carletto A, et al. A case of adult onset Still’s disease treated with infliximab [letter]. Clin Exp Rheumatol 2002 Jan–Feb; 20(1): 113
Dilhuydy MS, Vatan R, Etienne G, et al. Prolonged efficacy of infliximab for refractory adult-onset Still’s disease. Clin Exp Rheumatol 2005 Jan–Feb; 23(1): 121–2
Fautrel B, Sibilia J, Mariette X, et al. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis 2005 Feb; 64(2): 262–6
Benucci M, Li GF, Del Rosso A, et al. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still’s disease: the first case report [letter]. Clin Exp Rheumatol 2005 Sep–Oct; 23(5): 733
Iwamoto M, Nara H, Hirata D, et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still’s disease. Arthritis Rheum 2002 Dec; 46(12): 3388–9
Godinho F, Santos MJ, Canas Da Silva J. Refractory adult onset Still’s disease successfully treated with anakinra. Ann Rheum Dis 2005; 64: 647–8
Aelion J, Odhav S. Prompt response to treatment with anakinra in adult onset Still’s disease. Ann Rheum Dis 2004; 63 Suppl.: 281
Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum 2005 Jun; 52(6): 1794–803
Ortiz Z, Shea B, Suarez Almazor M, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD000951
Joyce DA, Will RK, Hoffman DM, et al. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991 Dec; 50(12): 913–4
Endresen GK, Husby G. Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis: an update and proposals for guidelines. Scand J Rheumatol 2001; 30(3): 129–34
Sathi N, Dawson J. Methotrexate-induced pancytopenia associated with co-prescription of penicillin and trimethoprim. Clin Rheumatol 2007 Jan; 26(1): 134–5
Michel M, Hayem G, Rat AC, et al. Fatal infectious complications in 2 patients with adult onset Still disease [in French]. Rev Med Interne 1996; 17(5): 407–9
Janssen HL, van Laar JM, van Hoek B, et al. Severe hepatitis and pure red cell aplasia in adult Still’s disease: good response to immunosuppressive therapy. Dig Dis Sci 1999 Aug; 44(8): 1639–42
Ott SJ, Baron A, Berghaus T, et al. Liver failure in adult Still’s disease during corticosteroid treatment. Eur J Gastroenterol Hepatol 2003 Jan; 15(1): 87–90
Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol Suppl 1985 Dec; 12 Suppl. 12: 35–9
Preet Singh Y, Aggarwal A, Misra R, et al. Low-dose methotrexate-induced pancytopenia. Clin Rheumatol 2007 Jan; 26(1): 84–7
Reginato AJ, Schumacher Jr HR, Baker DG, et al. Adult onset Still’s disease: experience in 23 patients and literature review with emphasis on organ failure. Semin Arthritis Rheum 1987 Aug; 17(1): 39–57
Weinblatt ME, Trentham DE, Fraser PA, et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988 Feb; 31(2): 167–75
Hunstad DA, French AR. Histoplasmosis in a child with JRA on low-dose methotrexate. Rheumatology (Oxford) 2007 Jan; 46(1): 177–8
Chim CS, Pang YY, Ooi GC, et al. EBV-associated synovial lymphoma in a chronically inflamed joint in rheumatoid arthritis receiving prolonged methotrexate treatment. Haematologica 2006 Aug; 91 (8 Suppl.): ECR31
Takeyama J, Sato A, Nakano K, et al. Epstein-Barr virus associated Hodgkin lymphoma in a 9-year-old girl receiving long-term methotrexate therapy for juvenile idiopathic arthritis. J Pediatr Hematol Oncol 2006 Sep; 28(9): 622–4
Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001 Sep 6; 345(10): 747–55
Singh S, Bansal A, Gupta A, et al. Kawasaki disease: a decade of experience from North India. Int Heart J 2005 Jul; 46(4): 679–89
Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 1994 Dec; 21(12): 2353–8
Mahmud T, Hughes GR. Intravenous immunoglobulin in the treatment of refractory adult Still’s disease. J Rheumatol 1999 Sep; 26(9): 2067–8
Vignes S, Wechsler B, Amoura Z, et al. Intravenous immunoglobulin in adult Still’s disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 1998 May–Jun; 16(3): 295–8
Permal S, Wechsler B, Cabane J, et al. Treatment of Still disease in adults with intravenous immunoglobulins. Rev Med Interne 1995; 16: 250–4
Kuek A, Weerakoon A, Ahmed K, et al. Adult-onset Still’s disease and myocarditis: successful treatment with intravenous immunoglobulin and maintenance of remission with etanercept. Rheumatology (Oxford) 2007 Jun; 46(6): 1043–4
Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007 Mar; 6(4): 257–9
Ryan ME, Webster ML, Statler JD. Adverse effects of intravenous immunoglobulin therapy. Clin Pediatrics 1996 Jan; 35(1): 23–31
Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006 Apr; 6(4): 535–42
Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gammaglobulin administration in patients with hypogam-maglobulinemia: detection of IgE antibodies to IgA. N Engl J Med 1986; 314: 550–4
Oh YB, Bae SC, Jung JH, et al. Secondary renal amyloidosis in adult onset Still’s disease: case report and review of the literature. Korean J Intern Med 2000 Jul; 15(2): 131–4
Kraetsch HG, Antoni C, Kalden JR, et al. Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis 2001 Nov; 60 Suppl. 3: iii55–7
Dechant C, Schauenberg P, Antoni CE, et al. Long-term outcome of TNF blockade in adult-onset Still’s disease [in German]. Dtsch Med Wochenschr 2004 Jun 4; 129(23): 1308–12
Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s disease. J Rheumatol 2003 Jul; 30(7): 1624–5
Olivieri I, de Stefano G, Padula A, et al. Infliximab in a case of early adult-onset Still’s disease. Clin Rheumatol 2003 Oct; 22(4-5): 369–70
Serratrice J, Granel B, Disdier P, et al. Resolution with etaner-cept of nephrotic syndrome due to renal AA amyloidosis in adult Still’s disease. Am J Med 2003 Nov; 115(7): 589–90
Kumari R, Uppal SS. Prolonged remission in adult-onset Still’s disease with etanercept. Clin Rheumatol 2006 Feb; 25(1): 106–8
Asherson RA, Pascoe L. Adult onset Still’s disease: response to Enbrel. Ann Rheum Dis 2002 Sep; 61(9): 859–60
Haraoui B, Bourrelle D, Kaminska E. Anakinra in the treatment of adult onset Still’s disease. Ann Rheum Dis 2004 Jul 1; 63 Suppl.: 293–4
Kotter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 2007 Dec; 37(3): 189–97
Kalliolias GD, Georgiou PE, Antonopoulos IA, et al. Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 2007 Jun; 66(6): 842–3
Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still’s disease successfully treated with anakinra. Ann Rheum Dis 2005 Apr; 64(4): 647–8
Rudinskaya A, Trock DH. Successful treatment of a patient with refractory adult-onset Still disease with anakinra. J Clin Rheumatol 2003 Oct; 9(5): 330–2
Quartuccio L, De Vita S. Interleukin 1 receptor antagonist therapy-induced thrombocytopenia in adult onset Still’s disease. J Rheumatol 2007 Apr; 34(4): 892–3
Chu C, Hughes G, Karr N, et al. Interleukin-1 blockade is an effective treatment of adult onset Still’s disease. Arthritis Rheum 2005; 52(12): 4101
Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993 Aug 1; 151(3): 1548–61
Efthimiou P, Markenson JA. Role of biological agents in immune-mediated inflammatory diseases. South Med J 2005 Feb; 98(2): 192–204
Agnholt J, Dahlerup JF, Kaltoft K. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 2003 Aug 7; 23(3): 76–8
Fleischmann R, Iqbal I, Nandeshwar P, et al. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf 2002; 25(3): 173–97
Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006 Jun; 54(6): 1987–94
La Montagna G, Valentini G. Listeria monocytogenes meningitis in a patient receiving etanercept for Still’s disease [letter]. Clin Exp Rheumatol 2005 Jan–Feb; 23(1): 121
Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004; 27(5): 307–24
Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005; 65(5): 661–94
Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007 Apr; 83(978): 251–60
Efthimiou P, Georgy S. Pathogenesis and management of adult-onset Still’s disease. Semin Arthritis Rheum 2006 Dec; 36(3): 144–52
Arend WP, Welgus HG, Thompson RC, et al. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990 May; 85(5): 1694–7
den Breeder AA, de Jong E, Franssen MJ, et al. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006 Jun; 65(6): 760–2
Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006 Aug; 65(8): 1006–12
Ruiz PJ, Masliah E, Doherty TA, et al. Cardiac death in a patient with adult-onset Still’s disease treated with the interleukin 1 receptor inhibitor anakinra. Ann Rheum Dis 2007 Mar; 66(3): 422–3
Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005 Mar; 52(3): 818–25
Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005; 7 (6): R1281–8
Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004 Aug; 4(4): 386–91
Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006 Sep; 54(9): 2817–29
Acknowledgements
No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this review article.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.2165/11585680-000000000-00000.
Rights and permissions
About this article
Cite this article
Kontzias, A., Efthimiou, P. Adult-Onset Still’s Disease. Drugs 68, 319–337 (2008). https://doi.org/10.2165/00003495-200868030-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200868030-00005